Camp4 Therapeutics Files 2026 Proxy Materials
Ticker: CAMP · Form: DEFA14A · Filed: Apr 23, 2026 · CIK: 0001736730
Sentiment: neutral
Topics: proxy, annual-meeting, sec-filing
TL;DR
Camp4 Therapeutics dropped proxy docs for their 2026 meeting. Shareholders get the scoop.
AI Summary
Camp4 Therapeutics Corp filed a Definitive Additional Materials (DEFA14A) on April 23, 2026, related to its 2026 annual meeting. The filing includes graphic materials, likely for shareholder communication. The company's mailing and business address is One Kendall Square, Cambridge, MA.
Why It Matters
This filing provides shareholders with important information regarding the company's 2026 annual meeting, influencing their voting decisions on corporate matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new financial or strategic information that would typically alter risk.
Key Players & Entities
- Camp4 Therapeutics Corp (company) — Filer of the DEFA14A
- 0001736730 (company) — CIK number for Camp4 Therapeutics Corp
- 2026-04-23 (date) — Filing date of the DEFA14A
- ONE KENDALL SQUARE BUILDING 1400 WEST, 3RD FLOOR CAMBRIDGE MA 02139 (location) — Mailing and Business Address for Camp4 Therapeutics Corp
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which stands for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
When was this filing made?
The filing date was April 23, 2026.
What is the CIK number for Camp4 Therapeutics Corp?
The CIK number for Camp4 Therapeutics Corp is 0001736730.
Where is Camp4 Therapeutics Corp located?
The company's mailing and business address is One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139.
What are the included document types in this filing?
The filing includes a DEFA14A document (defa14a-2026annualmeeting.htm), and two graphic files (defa14a2026image1.jpg and defa14a2026image2.jpg).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 23, 2026 regarding Camp4 Therapeutics Corp (CAMP).